Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026
DOI: 10.1111/ddg.15909 ↗At a glance
Klinische Studie in JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Written by Maike M Holtsche and 7 co-authors. Institution: Department of Dermatology, University of Lübeck, Lübeck, Germany. Major MEDLINE topics: Pemphigoid, Bullous, Immunosorbent Techniques. Cited 2 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA) in refractory patients. Here we investigated the safety and efficacy of IA in severe and/or refractory BP patients. Patients and Methods 10 BP patients (3 women, 7 men; mean age 69.7 years; range 52–81 years) were treated with IA on three consecutive days (LigaSorb ® , Fresenius Medical Care) combined with oral prednisolone (0.5 mg/kg BW per day, tapered), dapsone (1.5 mg/kg BW per day), and lesional mometasone furoate ointment.
Results
Within 2 and 6 months after IA, 50% and 90% of patients showed complete remission on therapy, respectively. In all patients, serum anti‐BP180 IgG levels decreased significantly by an average of 89% and 73% immediately after the third IA and 4 weeks later, respectively. A total of 56 adverse events (AE) occurred during the 12‐month follow‐up. The majority of AE were of severity grade 2 (50%), 15 AE were classified as severe (grade 3–4).
Conclusions
IA can be considered as a relatively safe and effective adjuvant therapy for patients with severe or refractory BP.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, University of Lübeck, Lübeck, Germany.
- Department of Dermatology, University of Oldenburg, Oldenburg, Germany.
- Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA.
- Department of Internal Medicine, University of Lübeck, Lübeck, Germany.
- Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
ORCID profiles: Maike M Holtsche, Artem Vorobyev
Cite
APA
Holtsche, M. M., van Beek, N., Hammers, C. M., Vorobyev, A., Kasperkiewicz, M., Schumacher, N., Muck, P., & Schmidt, E. (2026). Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15909
Vancouver
Holtsche MM, van Beek N, Hammers CM, Vorobyev A, Kasperkiewicz M, Schumacher N, et al. Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.15909
BibTeX
@article{Holtsche2026,
author = {Holtsche, Maike M and van Beek, Nina and Hammers, Christoph M and Vorobyev, Artem and Kasperkiewicz, Michael and Schumacher, Nina and Muck, Philip and Schmidt, Enno},
title = {Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2026},
doi = {10.1111/ddg.15909}
}
EUVIMED